ELTP · Elite Pharmaceuticals Inc /Nv/
$0.28
0.00 (-1.36%)
At close · Sep 2
Going-concern doubt
— cleared Aug 13, 2026
The latest filing no longer states the doubt (first flagged Jun 29, 2026).
View the 10-Q filed Aug 13, 2026Market Cap
$302.68M
Shares
1.08B
ELTP metrics
73 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$0.28
Market cap
$302.68M
Price action
19 metricsPrice change (1W)
-1.0%
Price change (30D)
-24.3%
Price change (3M)
-30.0%
Price change (6M)
-26.3%
Price change (YTD)
-42.9%
Price change (1Y)
-59.4%
Trailing year
Price change (5Y)
+460.0%
52-week high
$0.71
52-week low
$0.28
Change from 52-week high
-60.6%
Change from 52-week low
+0.0%
Annualized volatility
54.3%
Beta
0.6
RSI (14D)
22.0
Price vs SMA 50
-20.4%
Price vs SMA 200
-30.8%
Avg volume (3M)
727,444
Relative volume
0.3
Average dollar volume
$252,942
Company
3 metricsSector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
1.08B
Valuation
12 metricsP / E (TTM)
5.6
Trailing earnings · reciprocal yield 17.9%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
2.1×
reciprocal yield 46.6%
P / book
2.9
reciprocal yield 34.6%
FCF yield
5.8%
TTM · current market cap
Buyback yield
—
P / FCF
17.3
reciprocal yield 5.8%
P / operating cash flow
15.9
reciprocal yield 6.3%
Earnings yield
18.7%
Historical valuation
8 metricsP / E historical average (3Y)
19.4×
reciprocal yield 5.2%
P / E historical average (5Y)
14.4×
reciprocal yield 6.9%
EV / revenue historical average (3Y)
2.1×
reciprocal yield 47.5%
EV / revenue historical average (5Y)
2.1×
reciprocal yield 47.5%
EV / EBIT historical average (3Y)
20.9×
reciprocal yield 4.8%
EV / EBIT historical average (5Y)
20.9×
reciprocal yield 4.8%
EV / EBITDA historical average (3Y)
17.2×
reciprocal yield 5.8%
EV / EBITDA historical average (5Y)
17.2×
reciprocal yield 5.8%
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-14
Profitability
9 metricsGross margin
43.5%
Operating margin
24.8%
Trailing 12 months
Net margin
40.2%
Gross profit (TTM)
$61.31M
Operating profit (TTM)
$34.94M
Net income (TTM)
$56.67M
Trailing 12 months
Diluted EPS (TTM)
$0.05
FCF margin
12.4%
Effective tax rate
12.9%
Growth
11 metricsRevenue growth YoY
-19.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$141.01M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+5.6%
Year over year · more shares
Revenue CAGR (3Y)
+63.3%
Revenue CAGR (5Y)
+42.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
54.1%
Return on assets
40.6%
Debt / equity
—
Current ratio
3.8
EBITDA (TTM)
$35.99M
Free cash flow (TTM)
$17.53M
Quick ratio
3.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$39.42M
Total assets
$139.67M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
$19.04M
Capital expenditures (TTM)
$1.52M
R&D (TTM)
$6.10M
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
4.3%
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
1
13F filer change QoQ
0
Institutional ownership
0.0%
Short interest
3 metricsShort interest
0.2%
Latest settlement · 1.3 days to cover
Days to cover
1.3d
Short-squeeze score
22 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—